Liver Cancer
Copyright ©The Author(s) 2004.
World J Gastroenterol. May 1, 2004; 10(9): 1268-1275
Published online May 1, 2004. doi: 10.3748/wjg.v10.i9.1268
Table 1 Body and liver masses in each group of rats at end of the study (after 20 wk) (mean ± SE)
GroupNo. of ratsBody mass (g)Liver mass (g)Relative liver mass (g) (Liver/100 g body mass)
A6282.5 ± 15.8a14.6 ± 2.65.16 ± 0.47b
B10338.0 ± 18.310.8 ± 1.93.19 ± 0.21
C8334.3 ± 13.8c12.3 ± 1.83.67 ± 0.36e
D10348.9 ± 21.611.9 ± 1.53.41 ± 0.29
E8308.1 ± 19.113.1 ± 2.24.25 ± 0.45
F10336.6 ± 22.212.1 ± 1.83.59 ± 0.42
Table 2 Effect of 1α, 25(OH)2D3 on inhibition of GGT-positive foci in DEN induced rat hepatocarcinogenesis promoted by phenobarbital (mean ± SE)
GroupNo. of ratsNo. of GGT-positive foci/cm2Decrease (%)
A0 626.16±2.16
C0 88.16±0.59b68.8
E0 814.32±1.23d45.25
Table 3 Effect of 1α, 25(OH)2D3 on incidence, number and size of hepatocellular lessions during DEN induced rat hepatocarcinogenesis promoted by phenobarbital (mean ± SE)
GroupNo. of rats with nodulesNodule incidence (%)Total No. of noduleAverage No. of nodules per nodule bearing liverRelative size
< 1 mm> 1 mm, < 3 mm> 3 mm
A10/1010016816.80±1.3394 (55.95)48 (28.57)26 (15.47)
C6/1060b223.66±0.8811 (50.0)6 (27.27)05 (22.72)
E8/1080d728.00±1.0528 (38.88)24 (33.33)20 (27.77)
Table 4 Effect of 1α, 25dihydroxyvitamin D3 on DNA damage [based on mean tailed cells (%) and mean length: width ratios ± SEM of DNA pattern] in hepatic cells of rats during DEN in-duced rat hepatocarcinogenesis promoted by phenobarbital (mean ± SE, n = 100)
GroupsLength and width ratio of DNA massDecrease (%)Tailed cells (%)Decrease (%)
A2.44±0.068184±0.020
B1.029±0.00529±0.008
C1.12±0.025b54.0939±0.014d53.57
D1.02±0.000529±0.008
E1.63±0.026g33.1962±0.026f26.19
F1.02±0.00529±0.008
Table 5 Changes in activities of superoxide dismutase (units/mg protein) in different groups of rats treated with 1α, 25(OH)2D3 during DEN induced rat hepatocarcinogenesis promoted by phenobarbital (mean ± SE, n = 5)
GroupsNodulesSurroundingControl
A4.38 ± 0.56b5.28 ± 0.57a8.64 ± 0.87
C6.84 ± 0.81c7.60 ± 0.738.84 ± 0.80
E4.88 ± 0.665.64 ± 0.538.52 ± 0.77
Table 6 Changes in total hepatic lipid peroxidation (nmol MDA/100 mg protein) level in different groups of rats treated with 1α, 25(OH)2D3 during DEN induced rat hepatocarcinogenesis promoted by phenobarbital (mean ± SE, n = 5)
GroupsNodulesSurroundingControl
A18.72 ± 1.59b17.4 ± 1.34d2.44 ± 0.84
C8.80 ± 1.02a7.6 ± 0.883.16 ± 0.94
E13.16 ± 1.2312.32 ± 1.032.8 ± 0.79
Table 7 Changes in total hepatic reduced glutathione (GSH) (mg/100 g tissue) level in different groups of rats treated with 1α, 25(OH)2D3 during DEN induced rat hepatocarcinogenesis promoted by phenobarbital (mean ± SE, n = 5)
GroupsNodulesSurroundingControl
A367.6 ± 25.5b310.0 ± 24.9c226.0 ± 22.5
C268.0 ± 21.5a254.0 ± 20.1248.0 ± 21.7
E303.2 ± 22.5284.0 ± 21.6256.0 ± 22.5
Table 8 Changes in activity of 1-chloro-2,4-dinitro benzene (CDNB) conjugated (μmol CDNB conjugated/mg protein/mL) hepatic cytosolic glutathione S-transferase (GST) in different groups of rats treated with 1α, 25(OH)2D3 during DEN induced rat hepatocarcinogenesis promoted by phenobarbital (mean ± SE, n = 5)
GroupsNodulesSurroundingControl
A2.52 ± 0.23b1.54 ± 0.23c0.9 ± 0.10
C1.45 ± 0.27a1.24 ± 0.111.12 ± 0.13
E1.76 ± 0.291.48 ± 0.191.10 ± 0.11